Alto Neuroscience (ANRO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Alto Neuroscience (ANRO) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.01 of bullish evidence against -0.29 bearish.

Alto Neuroscience last closed at $24.01, -3.19% on the session.

Against the IVW growth benchmark the position is -4.11% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

2 graded predictions for ANRO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Alto Neuroscience in the 19th percentile on return on equity, where 100 is best.

Alto Neuroscience is classified under Health Care / Pharmaceuticals, with a market capitalisation of $973.20M.

StockMap tracks Alto Neuroscience as the 55th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Alto Neuroscience ranks 62nd of 128 in the group, against a group median of -0.24.